Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Siriporn C. Chattipakorn||en_US|
|dc.description.abstract||© 2019 British Society for Neuroendocrinology Lipocalin-2 (LCN2) has been known to play an important role in pathological conditions, specifically in response to inflammation, infection and injury to cells. Recently, several research teams have been interested in investigating its association with cognition during the progression of pathology. Previous studies have demonstrated that LCN2 is not correlated with cognitive function under normal physiological conditions, although LCN2 has been negatively associated with cognition and some neuropathologies. Increasing LCN2 production is associated with reduced cognitive performance in a rodent model. However, further studies are needed to explore the potential underlying mechanisms of LCN2 on cognitive dysfunction, as well as its clinical relevance. This review aims to summarise the evidence available from in vitro, in vivo and clinical studies concerning the possible role of LCN2 on cognitive function following the onset of pathological conditions. Any contradictory evidence is also assessed and presented.||en_US|
|dc.subject||Biochemistry, Genetics and Molecular Biology||en_US|
|dc.title||Lipocalin-2: Its perspectives in brain pathology and possible roles in cognition||en_US|
|article.title.sourcetitle||Journal of Neuroendocrinology||en_US|
|article.stream.affiliations||Chiang Mai University||en_US|
|Appears in Collections:||CMUL: Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.